Invesaro

Stocks Comparison

Incyte vs Maxcyte: revenue, profit, margins and growth compared

Incyte brought in $5.1B of revenue in fiscal 2025, Maxcyte $33M in fiscal 2025. Revenue changed by +21.2% at Incyte and -14.5% at Maxcyte on the year before, so Incyte grew faster. Incyte kept 25.0% of its revenue as net profit, Maxcyte -135.1%.

Side by side, latest fiscal year

INCYMXCT
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 31, 2025)
Revenue$5.1B$33M
Revenue growth+21.2%-14.5%
Net income$1.3B-$44.6M
Net margin25.0%-135.1%
Free cash flown/a-$36.2M
Free cash flow marginn/a-109.5%
Earnings per share (diluted)$6.41-$0.42
Cash$3.1B$20.1M
Debtn/an/a
Price to earnings19.3n/a
Market value$25.1B$120.8M
Dividend yieldn/an/a
Rank by revenue in sector#60 of 523 · Health care#390 of 523 · Health care

Over the years

Revenue
INCY FY2018: $1.9BINCY FY2019: $2.2BINCY FY2020: $2.7BINCY FY2021: $3BINCY FY2022: $3.4BINCY FY2023: $3.7BINCY FY2024: $4.2BINCY FY2025: $5.1BMXCT FY2019: $21.6MMXCT FY2021: $26.2MMXCT FY2021: $33.9MMXCT FY2022: $44.3MMXCT FY2023: $41.3MMXCT FY2024: $38.6MMXCT FY2025: $33MFY18FY19FY20FY21FY22FY23FY24FY25
INCY $5.1BMXCT $33M
Net income
INCY FY2018: $109.5MINCY FY2019: $446.9MINCY FY2020: -$295.7MINCY FY2021: $948.6MINCY FY2022: $340.7MINCY FY2023: $597.6MINCY FY2024: $32.6MINCY FY2025: $1.3BMXCT FY2019: -$12.9MMXCT FY2021: -$11.8MMXCT FY2021: -$19.1MMXCT FY2022: -$23.6MMXCT FY2023: -$37.9MMXCT FY2024: -$41.1MMXCT FY2025: -$44.6MFY18FY19FY20FY21FY22FY23FY24FY25
INCY $1.3BMXCT -$44.6M
Net margin
INCY FY2018: 5.8%INCY FY2019: 20.7%INCY FY2020: -11.1%INCY FY2021: 31.8%INCY FY2022: 10.0%INCY FY2023: 16.2%INCY FY2024: 0.8%INCY FY2025: 25.0%MXCT FY2019: -59.6%MXCT FY2021: -45.2%MXCT FY2021: -56.3%MXCT FY2022: -53.3%MXCT FY2023: -91.8%MXCT FY2024: -106.3%MXCT FY2025: -135.1%FY18FY19FY20FY21FY22FY23FY24FY25
INCY 25.0%MXCT -135.1%
Revenue growth
INCY FY2019: +14.7%INCY FY2020: +23.5%INCY FY2021: +12.0%INCY FY2022: +13.7%INCY FY2023: +8.9%INCY FY2024: +14.8%INCY FY2025: +21.2%MXCT FY2021: +21.0%MXCT FY2021: +29.5%MXCT FY2022: +30.6%MXCT FY2023: -6.7%MXCT FY2024: -6.4%MXCT FY2025: -14.5%FY19FY20FY21FY22FY23FY24FY25
INCY +21.2%MXCT -14.5%
Free cash flow
INCY FY2018: $262.7MINCY FY2019: $632.6MINCY FY2020: -$312MINCY FY2021: $568.5MINCY FY2022: $892.1MMXCT FY2019: -$10.1MMXCT FY2021: -$10.9MMXCT FY2021: -$14.5MMXCT FY2022: -$33.3MMXCT FY2023: -$25.4MMXCT FY2024: -$29.3MMXCT FY2025: -$36.2MFY18FY19FY20FY21FY22FY23FY24FY25
INCY $892.1MMXCT -$36.2M

Fiscal years as each company reports them; the two may end in different months.

Questions about Incyte and Maxcyte

Which is bigger by revenue, Incyte or Maxcyte?

Incyte is bigger by revenue: $5.1B in fiscal 2025, against $33M for Maxcyte in fiscal 2025.

Which keeps more of its revenue as profit, Incyte or Maxcyte?

Incyte had a net margin of 25.0% in fiscal 2025; Maxcyte had -135.1% in fiscal 2025.

Which grew revenue faster, Incyte or Maxcyte?

In their latest fiscal years revenue changed by +21.2% at Incyte and -14.5% at Maxcyte.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies